Notícias

PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.

Outside the U.S., volume climbed 113% against a 36% drop in realized prices

(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi

96,408 shares were disposed of following vesting of 245,000 performance stock units. Despite the sale, the CFO's total direct holdings grew to approximately 888,000 shares.

Galaxy Digital’s (NASDAQ: $GLXY) stock is down 5% after the crypto firm and artificial intelligence (A.I.) da...

A rough run continues for Nike.

Roblox stock shed more than 70% of its value in a year, yet Wall Street analysts and company insiders are moving in the opposite direction from the selloff. Here is what the conflicting signals actually mean for investors sitting on the sidelines.

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q2 2026 investor letter for the “Focused Equity Strategy.” A copy of the letter can be downloaded here. The Strategy reported a 0.8% gross return for the second quarter of 2026. Equity markets rallied after the first quarter’s Iran shock faded and […]

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

CEO Paul Prager said the company is transitioning from "platform formation" to "scaled execution" as it expands its AI infrastructure business.

IT solutions provider CDW (NASDAQGS:CDW) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 10% year on year to $6.57 billion. Its non-GAAP profit of $2.91 per share was 4% above analysts’ consensus estimates.

AMD Stock Falls 8% Despite Data Center Revenue Doubling

Oracle's AI Expansion Comes Under Pressure as Default Risk Surges

Revenue rose 92% and beat estimates in the first report as a public company

Galaxy Digital Inc. (GLXY) delivered earnings and revenue surprises of +75.00% and -18.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The last time he sold was in December 2022 with Bitcoin at $16,800. Will Jim's sales mark the bottom again?

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The "Big Short" investor said all his short positions remain profitable except his bet against Nvidia stock

Solar power systems company SolarEdge (NASDAQ:SEDG) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 19.6% year on year to $346.2 million. On the other hand, next quarter’s revenue guidance of $325 million was less impressive, coming in 12.6% below analysts’ estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.

Circle beat EPS estimates but missed on revenue in Q2 2026. Here is what CRCL traders should watch after the 9% jump.

Industrials products and automation company Regal Rexnord (NYSE:RRX) missed Wall Street’s revenue expectations in Q2 CY2026 as sales rose 4.2% year on year to $1.56 billion. Its non-GAAP profit of $2.99 per share was 15.7% above analysts’ consensus estimates.

The ride-hailing company's bookings and earnings forecasts for the current quarter came in below analyst expectations

While the S&P 500 just hit a record high and the AI trade roars back to life, one famous short seller is keeping his bearish bets intact and warning that the market's own mechanics could turn a celebration into a collapse.

Coupang (NYSE:CPNG) shares fell 5. 3% in pre-market trading after the South Korean e-commerce company released second-quarter 2026 results that fell short of revenue expectations and issued guidance pointing to continued pressure on profit margins.

Novo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its weight-loss treatments, but weaker-than-expected sales of its oral Wegovy medication and disappointing clinical trial results for a next-generation obesity therapy weighed heavily on investor sentiment. The company’s shares dropped 6% during US trading on Tuesday, while its Copenhagen-listed stock declined 4.

Global entertainment and media company Disney (NYSE:DIS) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.8% year on year to $25.25 billion. Its non-GAAP profit of $2.06 per share was 11.1% above analysts’ consensus estimates.

Investors were once again trying to make sense of comments from Elon Musk on Wednesday, after the SpaceX CEO said his rocket and AI company would exclusively use Nvidia chips from now on. AMD was the S&P 500's worst performer ahead of the opening bell, slumping 8.7% as Musk's announcement overshadowed a second-quarter earnings beat. Nvidia's own shares climbed 2%.

Citi has downgraded HSBC Holdings PLC (LSE:HSBA, NYSE:HSBC) to 'neutral' from 'buy', arguing that the shares need a breather after one of the strongest runs in the European banking sector this year. The stock is up 40% since January, and the bank now trades on roughly 11 times forward...

It's simpler than you might think to prepare for a market downturn.

Shares of SpaceX slumped more than 10% premarket to around $111 this morning, even after the rocket company reported a 92% surge in quarterly revenue. Investors were spooked by the company’s $18.4 billion in capital expenditure in the second quarter alone, which compared with just $2.8 billion in the prior year. “The concern for investors is how fast expenditure growth is outpacing revenue growth,” said Kathleen Brooks, research director at brokerage XTB.